Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by MDS Unit
Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial
To the Editor, Imetelstat is a first-in-class, direct and competitive inhibitor of telomerase enzymatic activity approved in the United States and Europe for adult patients with lower-risk myelodysplastic syndromes (LR-MDS) and red blood cell (RBC) transfusion-dependent (TD) anaemia (defined as requiring ≥4 RBC units over 8 weeks) who have relapsed or are refractory to or ineligible for erythropoiesis-stimulating agents (ESAs) based on the results of the pivotal phase 3 IMerge trial...
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial | Advances in Therapy
Abstract The efficacy of erythropoiesis-stimulating agents (ESAs) for transfusion-dependent (TD) anemia in lower-risk myelodysplastic syndromes (LR-MDS) is limited. Luspatercept achieved significantly greater rates of red blood cell (RBC) transfusion independence (TI) versus epoetin alfa (an ESA) in the phase 3 COMMANDS trial. This analysis assessed long-term RBC-TI, cumulative response, and safety with luspatercept in COMMANDS.
How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
INTRODUCTION Myelodysplastic syndromes/neoplasias (MDS) are a constellation of different diseases presenting anaemia as the most frequent cytopenia.1 In fact, anaemia shapes the clinical presentation and severity of the disease.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Summary Unmet medical needs remain in patients with red blood cell transfusion-dependent (RBC-TD) lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs). Imetelstat, a competitive telomerase inhibitor, showed promising results in a phase 2 trial. We aimed to compare the RBC transfusion independence (RBC-TI) rate with imetelstat versus placebo in patients with RBC-TD LR-MDS.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Summary Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durable clinical efficacy in patients with lower-risk myelodysplastic syndromes.
PIEZO1 mutations impact on early clinical manifestations of Myelodysplastic Syndromes
CORRESPONDENCE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ajh.26863.
Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts
Citation Vera Adema, Feiyang Ma, Rashmi Kanagal-Shamanna, Natthakan Thongon, Guillermo Montalban-Bravo, Hui Yang, Scott A. Peslak, Feng Wang, Pamela Acha, Francesc Sole, Pamela Lockyer, Margherita Cassari, Jaroslaw P. Maciejewski, Valeria Visconte, Irene Ganan-Gomez, Yuanbin Song, Carlos Bueso-Ramos, Matteo Pellegrini, Tuyet M. Tan, Rafael Bejar, Jennifer S. Carew, Stephanie Halene, Valeria Santini, Gheath Al-Atrash, Karen Clise-Dwyer, Guillermo Garcia-Manero, Gerd A.
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis - Leukemia
To the Editor: Myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a myeloid disorder with myelodysplastic and myeloproliferative features [1, 2]. MDS/MPN-RS-T-associated anemia causes fatigue, reduced quality of life, and worse survival [3,4,5].
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
Skip Nav Destination Letter to Blood| January 27, 2022
Targeting ineffective hematopoiesis in Myelodysplastic Syndromes
Email or Customer ID Please check your email for instructions on resetting your password. If you do not receive an email within 10 minutes, your email address may not be registered, and you may need to create a new Wiley Online Library account.
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Highlights: • This ESMO Clinical Practice Guideline provides key recommendations for managing myelodysplastic syndromes • It covers diagnosis, classification, staging and risk assessment of myelodysplastic syndromes • Treatment recommendations for lower- and higher-risk myelodysplastic syndromes are also provided • All recommendations were compiled by a multidisciplinary group of experts • Recommendations are based on available scientific data and the authors’ expert opinion Key words...
Of blood and bone: the sotatercept adventure
Challenges and new horizons for sickle cell disease
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with MDS
Contact MDS, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack